EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Biohybrids of Anoxia-Targeted Bacteria/MDPP for Enabling Targeted Synergistic Immunotherapy and Chemotherapy Against Breast Tumors

Tian Hu, Linsong Zhang, Yun Lu, Kang Xiong, Qian Wen, Jingrong Huang, Hongjun Deng, Kewei Xiang, Ping Zhou, Shaozhi Fu iD

International Journal of Nanomedicine · 2025

DOI: 10.2147/ijn.s515213 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2025. Verfasst von Tian Hu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunotherapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The hypoxic tumor microenvironment (TME) significantly impacts the effectiveness of various therapies on breast cancer. Conventional chemotherapeutic agents are unable to target hypoxic tumor tissue specifically, leading to reduced treatment efficacy and severe systemic toxicity. In order to improve drug targeting ability, we developed a bioactive biomotors system (MDPP@Bif) for chemoimmunotherapy against breast cancer. Utilizing the self-driving properties of the anaerobic Bifidobacterium infantis (B. infantis, Bif), both doxorubicin (DOX) and anti-programmed cell death protein ligand-1 (αPD-L1) antibody can be delivered simultaneously to tumor tissues to exert an anti-tumor effect on breast cancer.

Methods

The physicochemical properties of diverse nano-formulations were systematically characterized. In vitro anti-tumor efficacy of the MDPP@Bif biomotors was assessed through comprehensive biological evaluations, including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, live/dead staining, c cellular uptake analysis, apoptosis quantification, and wound healing assays to evaluate the in vitro anti-tumor activity of the MDPP@Bif biomotors. Furthermore, the therapeutic potential of the MDPP@Bif biohybrids was validated in vivo using a murine breast cancer model by monitoring of tumor growth kinetics, body weight fluctuations, and survival outcomes. Immunofluorescence staining was also used to further validate T-cells infiltration in the tumor tissues.

Results

The developed MDPP@Bif biomotors can actively colonize hypoxic tumor tissues through Bif's inherent targeting ability, releasing DOX to inhibit tumor growth. The released αPD-L1 antibody specifically binds to PD-L1, reducing immune escape and activating T cells. The concentration of DOX in tumor tissues of the MDPP@Bif group was 2.5 times higher than in tumors treated with free DOX, significantly prolonging the median survival of mice to 62 days and reducing the toxic side effects of DOX.

Conclusion

The novel bacteria-propelled biomotor MDPP@Bif shows great potential in treating solid tumors through synergistic chemotherapy and immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsImmunotherapyAnimalsFemaleDoxorubicinMiceHumansTumor MicroenvironmentCell Line, TumorMice, Inbred BALB CB7-H1 AntigenApoptosisXenograft Model Antitumor AssaysAntineoplastic Agents

Stichwörter der Autor:innen

anaerobic bacteriaanti-PD-L1 antibodybreast cancerchemoimmunotherapydoxorubicinmesoporous silica nanoparticles

Substanzen

DoxorubicinB7-H1 AntigenAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Oncology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
  • Department of Oncology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
  • Department of Radiology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
  • Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan, 646000, People's Republic of China.

ORCID-Profile: Shaozhi Fu

Zitieren

APA

Hu, T., Zhang, L., Lu, Y., Xiong, K., Wen, Q., Huang, J., Deng, H., Xiang, K., Zhou, P., & Fu, S. (2025). Biohybrids of Anoxia-Targeted Bacteria/MDPP for Enabling Targeted Synergistic Immunotherapy and Chemotherapy Against Breast Tumors. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s515213

Vancouver

Hu T, Zhang L, Lu Y, Xiong K, Wen Q, Huang J, et al. Biohybrids of Anoxia-Targeted Bacteria/MDPP for Enabling Targeted Synergistic Immunotherapy and Chemotherapy Against Breast Tumors. International Journal of Nanomedicine. 2025. doi:10.2147/ijn.s515213

BibTeX
@article{Hu2025,
  author = {Hu, Tian and Zhang, Linsong and Lu, Yun and Xiong, Kang and Wen, Qian and Huang, Jingrong and Deng, Hongjun and Xiang, Kewei and Zhou, Ping and Fu, Shaozhi},
  title = {Biohybrids of Anoxia-Targeted Bacteria/MDPP for Enabling Targeted Synergistic Immunotherapy and Chemotherapy Against Breast Tumors},
  journal = {International Journal of Nanomedicine},
  year = {2025},
  doi = {10.2147/ijn.s515213}
}
Kostenlos starten →